. . . . . "S&T TWOC Project - version 4" . "S&T TWOC version 3" . "2"^^ . "2023-07-20T09:47:22.671981"^^ . . . "antivirals like remdesivir , lopinavir , ritonavir , arbidol , oseltamivir , penciclovir , favipiravir , ganciclovir , and ribavirin ;" . "(60, 66)" . "including" . "67" . "different pharmacological groups" . "(60, 66)" . "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." . "8j41d0a3" . "8j41d0a3-TRIPLE-ABSTRACT-1" . "groups" . "arbidol" . "RSA" . "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" . "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" . . .